Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of brain tumors

BMJ talk medicine

Survival for glioblastoma remains very poor despite decades of research, with a 5-year survival of only 5%. Technological improvements that have revolutionized treatment of ischemic stroke and brain aneurysms have great potential in providing more precise and selective delivery of cancer therapeutic agents to brain tumors. In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque speaks with Dr. Stephen Chen (1)and Dr. Peter Kan (2) about their paper "Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors". The paper describes a technique using perfusion guidance to enhance the precision of endovascular super-selective intra-arterial (ESIA) infusions of mesenchymal stem cells loaded with Delta-24 in the treatment of glioblastoma. This technique enhances targeted super-selective delivery of therapeutic agents for brain tumors. Paper available online (https://jnis.bmj.com/content/14/6/533) and in June print issue of JNIS. Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767 Thank you for listening! This episode was produced by Leticia Amorim and edited by Brian O'Toole. (1) Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA (2) Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA